Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study

Wirth, Stefan; Zhang, Hongfei; Hardikar, Winita; B. Schwarz, Kathleen; Sokal, Étienne; Yang, Weibo; Fan, Huimin; Morozov, Vyacheslav; Mao, Qing; Deng, Hong; Huang, Yang; Yang, Lei; Frey, Nicolas; Nasmyth‐Miller, Clare; Pavlovic, Vedran; Wat, Cynthia

doi:10.1002/hep.30050

Public

Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study

Published in Hepatology • Apr 24, 2018

Authors:

Stefan Wirth

Hongfei Zhang

Winita Hardikar

Abstract

Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG‐B‐ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa‐2a treatment i...

Subject

Medicine

Chronic hepatitis

PEG ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!